Dr David Thompson, editor of Value and Outcome Spotlight, asks whether the emergence of gene therapies and cancer immunotherapies has exposed "critical limitations in the tools and techniques" of health technology assessment.
Latest Video
New Stories
-
Gilead announces eight recipients of inaugural Community Grants Program
March 28, 2024 - - Latest News -
Groups call for a new approach to reviewing and funding cancer medicines
March 28, 2024 - - Latest News -
Auditor General extends time to contribute to PBS performance audit
March 28, 2024 - - Latest News -
Reform bill redefines political donation and could exclude the industry from participating
March 27, 2024 - - Latest News -
NZ Government delivers funding boost for patients travelling to health treatment
March 27, 2024 - - Latest News -
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 - - Australian Biotech -
More states announce RSV programs as families call for national action
March 26, 2024 - - Latest News